PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

West German Study Group

Status: Completed

Conditions: Breast Cancer

Treatments: Other: MammaPrint; Other: TargetPrint; Other: BluePrint

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02269813

WSG-PRIMe

Details and patient eligibility

About

PRIMe is a prospective, case-only trial designed to measure the impact of MammaPrint on physician chemotherapy intention in the two discordant groups (ET/POOR, CT/GOOD) in stage 1 and 2 HR-positive HER2-negative breast cancer patients. The design also provides for assessment of several important secondary indicators. Eligible patients will have their tumor sample analyzed for MammaPrint, BluePrint and TargetPrint. Patients cannot start treatment before the MammaPrint result is received and taken into consideration for the adjuvant treatment plan.

Enrollment: 452 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with histologically proven invasive stage 1 and 2 breast cancer
• Hormone receptor positive according to local standards
• HER2 negative - i.e. IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)
• Axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)
• ≥ 18 years of age at time of consent
• Patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
• Written informed consent

Exclusion criteria

• ≥4 involved axillary nodes
• Multi-centric disease with more than 2 clinically relevant lesions
• HR negative OR HER2 positive/amplified (locally assessed)
• Previous diagnosis of malignancy unless disease free for 10 years
• Metastatic disease
• Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
• Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer

Trial design

452 participants in 2 patient groups

ET/GOOD

Description:

Endocrine therapy only.

Treatment:

Other: TargetPrint

Other: MammaPrint

Other: BluePrint

CT/POOR

Description:

Chemoendocrine therapy according to national guidelines.

Treatment:

Other: TargetPrint

Other: MammaPrint

Other: BluePrint